COVID-19 Vaccine Candidate Well Tolerated in Older Adults
A messenger RNA coronavirus disease 2019 (COVID-19) vaccine was well tolerated in older adults.
Related Articles
Accurate, Complete Data Entry Is Key to Medication Safety
Carefully checking every piece of information and proofreading for accuracy is crucial to ensure patient safety
Advocate for Greater Pharmacy Technician Roles
Multiple state and federal laws since the COVID-19 pandemic highlight the growing role of technicians
Recombinant Zoster Vaccine Demonstrates High Protection Against Shingles in Adult Patients
The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.
FDA Approves Pivmecillinam for Treatment of Female Adults With Urinary Tract Infections
Pivmecillinam (Pivya; UTILITY therapeutics Ltd) tablets were approved for female adults with uncomplicated urinary tract infection caused by Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
CDC Confirms Case of H5N1 Bird Flu in the United States, Noting Risk to Public Health Remains Low
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
Considerations When Treating Migraines in Gender Diverse Patients Receiving Gender-Affirming Hormone Therapy
The AAN speaker highlights what health care providers need to know when treating migraines in populations on hormone therapy, as well as how hormones can…
FDA Approves Ankiva Plus Bacillus Calmette-Guérin For Non-Muscle Invasive Bladder Cancer
The approval was based on the QUILT-3.032 study, which included 77 adults with carcinoma in situ with or without papillary tumors after a transurethral resection.
FDA Approves Ankiva Plus Bacillus Calmette-Guérin For Non-Muscle Invasive Bladder Cancer
The approval was based on the QUILT-3.032 study, which included 77 adults with carcinoma in situ with or without papillary tumors after a transurethral resection.
FDA Approves Lutathera for Pediatric Patients With SSTR+ Gastroenteropancreatic Neuroendocrine Tumors
This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.
Counsel Patients About Self-Care Measures, OTC Treatments for Seasonal Allergies
Proper diagnosis and selection of products is crucial to management of hay fever